All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is currently the standard of care for treatment-naïve patients with diffuse large B-cell lymphoma (DLBCL). However, over one-third of patients are not cured by R-CHOP treatment. Thus, new frontline treatment options are needed for patients with DLBCL, particularly for those who have inferior outcomes with R-CHOP.
Below, we summarize key data from a recent article published in Journal of Clinical Oncology and presentations from the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on novel frontline treatment combinations in DLBCL. Davies et al. highlighted improved outcomes in DLBCL molecular subgroups with the addition of bortezomib to R-CHOP chemoimmunotherapy, based on 5-year survival results from the REMoDL-B trial1, 2; while Topp et al. presented the favorable response rates and safety profile of glofitamab plus R-CHOP in patients with previously untreated DLBCL, from a phase Ib study.3
REMoDL-B (NCT01324596) was an open-label, randomized, phase III trial investigating frontline R-CHOP + bortezomib (RB-CHOP) chemoimmunotherapy in patients with DLBCL. The study was conducted between June 2011 and June 2015 across 107 sites in the UK and Switzerland. Eligible patients were randomized to receive R-CHOP or RB-CHOP from Cycle 2 and stratified by cell-of-origin as per gene expression profile analysis.
The primary endpoints were progression-free survival (PFS) in R-CHOP vs RB-CHOP study arms and evaluation of DLBCL molecular phenotype (ABC/MHG/GCB) effect on potential benefit derived from the addition of bortezomib. Secondary endpoints included overall survival (OS), toxicity, and quality of life.
At a median follow-up of 60 months, there was no overall difference in PFS and OS between R-CHOP and RB-CHOP groups;
The addition of bortezomib improved PFS and OS for RB-CHOP treated patients in the ABC and MHG subgroups (Figure 1), but not in the GCB subgroup (data not shown). In summary, 5-year PFS improved by 15% and 26% in the ABC and MHG subgroups, respectively, and a 13% improvement in 5-year OS was observed in the ABC subgroup.
There were no differences in outcomes by treatment arm in any of the subgroups by LymphGen classification.
Figure 1. Five-year survival outcomes in the ABC and MHG subgroups*
PFS, progression-free survival; OS, overall survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RB-CHOP, R-CHOP + bortezomib.
*Adapted from Davies, et al.1
The addition of bortezomib was well tolerated and 5-year follow-up safety data was similar to the preliminary analysis of the trial at a median 30-month follow-up; no new adverse events (AEs) were reported. More serious AEs were reported in the RB-CHOP group vs the R-CHOP group (50.7% and 42.5%, respectively). There were four and five treatment-related deaths in the BR-CHOP group and R-CHOP group, respectively. BR-CHOP was not associated with increased hematological toxicity.
The addition of bortezomib to frontline R-CHOP treatment improved survival outcomes in patients with DLBCL, specifically in ABC and MHG subtypes. Gene expression profiling can help identify molecular subtypes of DLBCL that may benefit from the addition of bortezomib to initial therapy.
This was a phase Ib, multi-center study of glofitamab + R-CHOP (G/R-CHOP) in patients with DLBCL (NCT03467373). A total of six to eight 21-day cycles of R-CHOP were administered to patients included in the study. In Cycle (C) 1, R-CHOP was given followed by intravenous glofitamab (2.5/10/30 mg) during C2 (Day [D] 8, 2.5 mg; D15, 10 mg), with the target dose (30 mg) given from C3D8 onwards. Hospitalization was at the discretion of the investigator for patients enrolled in the expansion stage.
The study aimed to assess the efficacy and safety of G/R-CHOP from the run-in portion and expansion stage of the study.
Overall, 56 patients received R-CHOP (safety population) and 53/56 patients received glofitamab in addition to R-CHOP. At baseline, the majority of patients had a high tumor burden.
After a median 5.6-month follow-up, promising response rates were observed with G/R-CHOP in the end of treatment population (Table 1).
Table 1. Response rates*
Efficacy endpoint, % |
R-CHOP |
G/R-CHOP |
|
---|---|---|---|
EOT response |
|||
CMR rate |
72.7 |
75.5 |
|
Overall response rate |
83.6 |
86.8 |
|
Best overall response§ |
|||
CMR rate |
72.7 |
75.5 |
|
Overall response rate |
92.7 |
96.2 |
|
CMR, complete molecular response; EOT, end of treatment; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; G/R-CHOP, glofitamab+R-CHOP. |
G/R-CHOP frontline treatment showed overall promising and consistent antitumor activity in treated patients.
The hospitalization requirement was removed following the safety run-in and the subsequent 42 patients were treated without mandatory hospitalization.
Table 2. Safety profile*
Parameter, n |
Safety population |
---|---|
Total AEs |
55 |
Related to glofitamab |
32 |
Grade 3/4 AE |
36 |
Related to glofitamab |
13 |
Grade 5 AE† |
4 |
Related to glofitamab |
0 |
Serious AE |
18 |
Related to glofitamab |
5 |
AE leading to discontinuation of glofitamab‡ |
1 |
AE leading to dose modification/interruption of glofitamab |
12 |
CRS (any grade) |
6 |
Grade 1 |
4 |
Grade 2 |
2 |
Grade ≥3 |
0 |
Serious AE of CRS (any grade) |
2 |
Median time to 1st CRS event, hours§ |
10.2 |
Tocilizumab for CRS management‖ |
2/6 |
CRS resolved |
6/6 |
Other AEs of interest |
|
Neurological AEs¶ |
22 |
Grade 1 |
16 |
Grade 2 |
4 |
Grade 3# |
2 |
Infections |
22 |
Serious infections |
9 |
COVID-19 |
8 |
Sepsis |
1 |
Neutropenia |
25 |
Grade ≥3 |
23 |
Febrile neutropenia** |
7 |
AE, adverse event; CRS, cytokine release syndrome; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; G/R-CHOP, glofitamab+R-CHOP. |
The presented data suggest that G/R-CHOP can be safely used in combination as a frontline fixed-duration treatment for patients with DLBCL considering the low incidence and severity of cytokine release syndrome, minimal toxicity, and promising efficacy reported. All patients received R-CHOP at the same dose intensity and the use of GR-CHOP in an outpatient setting may also be appropriate.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox